DERMATOLOGY company Botanix Pharmaceuticals Limited has been officially included yesterday in the Australian Securities Exchange (ASX) All Ordinaries Index (All Ords).
The listing comes as a recognition of the company's strong share performance over the past year and aligns it with the 500 largest companies listed on the ASX.
From its bases in Philadelphia and Phoenix, United States, Botanix expressed honour in joining the ranks of the All Ords, marking a period of significant growth and investor confidence.
Central to the company's rising share performance is its first and second line medical treatment for excessive underarm sweating, known as Sofpironium Bromide gel, Sofdra, which is awaiting approval from the US Food and Drug Administration, expected by late Jun 2024.
Howie McKibbon, Botanix Chief Executive Officer, commented, "we are humbled to acknowledge the confidence investors have shown in our company, as exemplified by our inclusion in the ASX All Ordinaries Index."
McKibbon believes the "generous investments" made in Botanix positioned it well for a successful product launch, with preparations underway, further solidifying the company's market position. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Apr 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Apr 24
